Novel situations of endothelial injury in stroke - Mechanisms of stroke and strategy of drug development: Intracranial bleeding associated with the treatment of ischemic stroke: Thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator

Journal of Pharmacological Sciences

Volumn 116, Issue 1, 2011, Pages 25-29

  Suzuki, Yasuhiro ^a   Nagai, Nobuo ^b   Umemura, Kazuo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Cerebral ischemia; Endothelial injury; Intracranial hemorrhage; Low density lipoprotein receptor related protein; Matrix metalloproteinase; Tissue type plasminogen activator

Indexed keywords

DISUFENTON SODIUM; FREE RADICAL; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MATRIX METALLOPROTEINASE; NEUROPROTECTIVE AGENT; NORPHENAZONE; PLASMIN; RECEPTOR ASSOCIATED PROTEIN; STROMELYSIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADVERSE OUTCOME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBRINOLYTIC THERAPY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REPERFUSION INJURY; SHORT SURVEY;

EID: 79956198341     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R27FM     Document Type: Short Survey

References (34)

1. Hankey G, Sudlow C, David W. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke. 2000;31:1779-1784. (Pubitemid 30437537)
2. Linkins L, Choi P, Douketis J. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900.
3. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
4. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke. 1984;15:779-789.
5. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
6. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355:1205-1210.
7. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol. 2010;9:959-968.
8. Fletcher A, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks JE, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke. 1976;7:135-142.
9. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
10. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, et al. MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38:2633-2639.
11. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick J, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
12. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. (Pubitemid 46138121)
13. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.
14. Lijnen H, Collen D. Tissue-type plasminogen activator. Ann Biol Clin (Paris). 1987;45:198-201. (Pubitemid 17119652)
15. Suzuki Y, Nagai N, Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haemost. 2004;2:1617-1621. (Pubitemid 40186179)
16. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600. (Pubitemid 43209106)
17. Shuaib A, Lees K, Lyden P, Grotta J, Davalos A, Davis S, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571. (Pubitemid 47236281)
18. Lijnen H. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324-333. (Pubitemid 32663963)
19. Lapchak P, Chapman D, Zivin J. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034-3040.
20. Sumii T, Lo E. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836. (Pubitemid 34204013)
21. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen H. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost. 2007;5:1732-1739. (Pubitemid 47091418)
22. Wang X, Lee S, Arai K, Lee S, Tsuji K, Rebeck G, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-1317. (Pubitemid 37279856)
23. Nagase H, Woessner J Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494. (Pubitemid 129519680)
24. Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Umemura K. Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood. 2009;114:3352-3358.
25. Hu K, Wu C, Mars W, Liu Y. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest. 2007;117:3821-3832. (Pubitemid 350224092)
26. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley K. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988;7:4119-4127.
27. Bu G, Williams S, Strickland D, Schwartz A. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1992;89:7427-7431.
28. Lillis A, Van Duyn L, Murphy-Ullrich J, Strickland D. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88:887-918.
29. Rigau V, Morin M, Rousset M, Bock F, Lebrun A, Coubes P, et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain. 2007;130:1942-1956. (Pubitemid 47343810)
30. Cheng S, Xing B, Li J, Cheung B, Lau A. Interferon-gamma regulation of TNFalpha-induced matrix metalloproteinase 3 expression and migration of human glioma T98G cells. Int J Cancer. 2007;121:1190-1196. (Pubitemid 47293784)
31. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci U S A. 1999;96:5668-5673. (Pubitemid 29234676)
32. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13:781-792. (Pubitemid 29220691)
33. Zhang X, Polavarapu R, She H, Mao Z, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptorrelated protein mediate cerebral ischemia-induced nuclear factorkappaB pathway activation. Am J Pathol. 2007;171:1281-1290. (Pubitemid 47582901)
34. Coussens L, Fingleton B, Matrisian L. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387-2392. (Pubitemid 34270240)